PL2968306T3 - Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka - Google Patents
Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego okaInfo
- Publication number
- PL2968306T3 PL2968306T3 PL14764546.9T PL14764546T PL2968306T3 PL 2968306 T3 PL2968306 T3 PL 2968306T3 PL 14764546 T PL14764546 T PL 14764546T PL 2968306 T3 PL2968306 T3 PL 2968306T3
- Authority
- PL
- Poland
- Prior art keywords
- nicotinamid
- mononucleotide
- administration
- treatment
- dry eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801188P | 2013-03-15 | 2013-03-15 | |
| US201461947387P | 2014-03-03 | 2014-03-03 | |
| PCT/US2014/030920 WO2014146044A1 (en) | 2013-03-15 | 2014-03-17 | Administration of nicotinamide mononucleotide in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2968306T3 true PL2968306T3 (pl) | 2024-01-29 |
Family
ID=51538175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14764546.9T PL2968306T3 (pl) | 2013-03-15 | 2014-03-17 | Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US9844561B2 (pl) |
| EP (2) | EP4233878A1 (pl) |
| ES (1) | ES2952032T3 (pl) |
| PL (1) | PL2968306T3 (pl) |
| WO (1) | WO2014146044A1 (pl) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
| JP2018100222A (ja) * | 2015-04-20 | 2018-06-28 | 学校法人慶應義塾 | 角膜損傷の治療剤、改善剤または予防剤 |
| US20180177703A1 (en) * | 2015-06-25 | 2018-06-28 | N.V. Perricone Llc | Niacinamide Mononucleotide Formulations For Skin Aging |
| JP6949002B6 (ja) | 2015-08-05 | 2021-11-17 | メトロ インターナショナル バイオテック，エルエルシー | ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| WO2018030389A1 (ja) * | 2016-08-08 | 2018-02-15 | 学校法人 慶應義塾 | Ｎａｄ関連代謝産物の利用 |
| WO2018052019A1 (ja) * | 2016-09-13 | 2018-03-22 | めぐみ 田中 | 視覚機能改善剤及び視覚機能の改善方法 |
| EP3578639A4 (en) * | 2017-01-31 | 2020-07-08 | Oriental Yeast Co., Ltd. | AGENT FOR ACCELERATING THE GROWTH OF STEM CELLS WITH DIFFERENTIATION POTENTIAL |
| JP7374585B2 (ja) | 2017-02-08 | 2023-11-07 | オリエンタル酵母工業株式会社 | 皮膚色素沈着抑制剤 |
| JP6920071B2 (ja) * | 2017-02-16 | 2021-08-18 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | アディポネクチン分泌向上剤 |
| JP6917239B2 (ja) * | 2017-08-03 | 2021-08-11 | 旭化成ファーマ株式会社 | タンパク質およびその製造方法、タンパク質組成物ならびにそれを用いたｎｍｎの測定方法および測定組成物 |
| JP2020530460A (ja) * | 2017-08-10 | 2020-10-22 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | ニコチンアミドモノヌクレオチドを使用する治療の組成物および方法 |
| CN111093397A (zh) * | 2017-09-14 | 2020-05-01 | 田中惠 | 一种抗衰老剂以及抗衰老方法 |
| WO2019152416A1 (en) | 2018-01-30 | 2019-08-08 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| EP3770268A4 (en) | 2018-03-20 | 2021-12-22 | Mitsubishi Corporation Life Sciences Limited | METHOD OF PRODUCTION OF ß-NMN AND COMPOSITION IN CONTAINER |
| WO2019182044A1 (ja) | 2018-03-22 | 2019-09-26 | オリエンタル酵母工業株式会社 | 多分化能性幹細胞分化促進剤 |
| CA3103825A1 (en) * | 2018-05-15 | 2019-11-21 | Jumpstart Fertility Pty Ltd | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents |
| EP3850954A4 (en) * | 2018-09-14 | 2022-06-08 | Megumi Tanaka | ANTI-AGING AGENT AND ANTI-AGING PROCESS |
| CN109939120B (zh) * | 2019-03-01 | 2020-01-31 | 北京慧宝源生物技术股份有限公司 | 含烟酰胺单核苷酸和罗汉果苷的组合物及其应用 |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| PL3991795T3 (pl) * | 2019-06-25 | 2025-01-13 | Senju Pharmaceutical Co., Ltd. | Nowe zastosowanie mononukleotydu nikotynamidu (nmn) i rybozydu nikotynamidu (nr) |
| AU2020324248A1 (en) * | 2019-08-06 | 2022-03-10 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Pharmaceutical composition producing safe amount of nitric oxide in body and use thereof |
| EP4122536A4 (en) * | 2020-03-16 | 2024-04-24 | Megumi Tanaka | COENZYME Q PRODUCTION PROMOTER AND METHOD FOR PROMOTING COENZYME Q PRODUCTION |
| WO2021231860A1 (en) * | 2020-05-14 | 2021-11-18 | Primo Pharmatech Llc | Solid dosage form for transmucosal drug delivery |
| CN112089706A (zh) * | 2020-09-28 | 2020-12-18 | 深圳雾件科技有限公司 | 一种烟酰胺单核苷酸缓释微丸及其制备方法 |
| JP7553335B2 (ja) | 2020-11-30 | 2024-09-18 | 日清ファルマ株式会社 | β－ニコチンアミドモノヌクレオチド含有製剤 |
| CN112569249A (zh) * | 2020-12-29 | 2021-03-30 | 中科健康产业集团股份有限公司 | 一种具有抗衰老作用的番茄红素组合物的制备方法 |
| EP4277627A4 (en) * | 2021-01-14 | 2024-10-30 | Bioenergy Life Science, Inc. | METHODS AND COMPOSITIONS FOR INCREASING NAD+ METABOLISM IN HEALTHY MIDDLE-AGED POPULATION |
| CN113133981A (zh) * | 2021-04-20 | 2021-07-20 | 北京天玺宝科技有限公司 | β-烟酰胺单核苷酸口崩片及其制备方法 |
| KR20240020716A (ko) | 2021-05-27 | 2024-02-15 | 메트로 인터내셔널 바이오테크 엘엘씨 | 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법 |
| JP2023005922A (ja) * | 2021-06-29 | 2023-01-18 | 株式会社常磐植物化学研究所 | サーチュイン活性化剤 |
| US11571438B1 (en) * | 2022-05-23 | 2023-02-07 | Sasan Akhavan | Nutraceutical compositions to up-regulate SIRT1 and methods of use |
| AU2023307487A1 (en) | 2022-07-15 | 2025-01-23 | Danstar Ferment Ag | Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+ |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| JP2008501343A (ja) * | 2004-06-04 | 2008-01-24 | ワシントン・ユニバーシティ | 神経障害を治療するための方法および組成物 |
| US8268575B2 (en) | 2004-09-20 | 2012-09-18 | Washington University | NAD biosynthesis systems |
| EP1877054A2 (en) | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20070014833A1 (en) | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| CA2609549A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| US7737158B2 (en) | 2005-10-11 | 2010-06-15 | Washington University | Processes for regulating blood glucose in a mammal |
| CA2676609A1 (en) | 2007-01-26 | 2008-07-31 | Washington University | Methods and compositions for treating neuropathies |
| EP2057905A1 (en) | 2007-11-12 | 2009-05-13 | TIMA Foundation | Composition for moderating Triglyceride and Cholesterol Levels |
| CN101601679B (zh) | 2009-03-17 | 2011-08-10 | 中国人民解放军第二军医大学 | 一种烟酰胺单核苷酸的应用 |
| DE102010030911A1 (de) | 2010-07-02 | 2012-01-05 | Kunststoff-Technik Scherer & Trier Gmbh & Co Kg | Verfahren zur Herstellung eines Formteils und Formteil |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20140221319A1 (en) * | 2011-06-29 | 2014-08-07 | Mayo Foundation For Medical Education And Research | Small Molecule CD38 Inhibitors and Methods of Using Same |
| EP3495470A1 (en) | 2011-06-29 | 2019-06-12 | The General Hospital Corporation | In vivo methods for enhancing bioenergetic status in female germ cells |
-
2014
- 2014-03-17 PL PL14764546.9T patent/PL2968306T3/pl unknown
- 2014-03-17 EP EP23169080.1A patent/EP4233878A1/en active Pending
- 2014-03-17 WO PCT/US2014/030920 patent/WO2014146044A1/en active Application Filing
- 2014-03-17 EP EP14764546.9A patent/EP2968306B1/en active Active
- 2014-03-17 ES ES14764546T patent/ES2952032T3/es active Active
-
2015
- 2015-09-15 US US14/855,293 patent/US9844561B2/en active Active
-
2017
- 2017-10-13 US US15/783,845 patent/US10258638B2/en active Active
-
2019
- 2019-03-01 US US16/290,122 patent/US10925888B2/en active Active
-
2021
- 2021-01-15 US US17/150,584 patent/US11793824B2/en active Active
-
2023
- 2023-09-21 US US18/471,764 patent/US12150950B2/en active Active
-
2024
- 2024-10-28 US US18/928,703 patent/US20250049833A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160022712A1 (en) | 2016-01-28 |
| US20250049833A1 (en) | 2025-02-13 |
| EP4233878A1 (en) | 2023-08-30 |
| US12150950B2 (en) | 2024-11-26 |
| US10925888B2 (en) | 2021-02-23 |
| US20180050054A1 (en) | 2018-02-22 |
| US20210346413A1 (en) | 2021-11-11 |
| EP2968306A4 (en) | 2016-11-02 |
| US9844561B2 (en) | 2017-12-19 |
| US20190224223A1 (en) | 2019-07-25 |
| US20240009222A1 (en) | 2024-01-11 |
| WO2014146044A1 (en) | 2014-09-18 |
| US10258638B2 (en) | 2019-04-16 |
| EP2968306A1 (en) | 2016-01-20 |
| ES2952032T3 (es) | 2023-10-26 |
| US11793824B2 (en) | 2023-10-24 |
| EP2968306B1 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2968306T3 (pl) | Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka | |
| HUE058737T2 (hu) | Eljárások arenaviridae vírusok okozta fertõzések kezelésére | |
| HK1246296A1 (zh) | 多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途 | |
| PL3936130T3 (pl) | Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu | |
| RS60767B1 (sr) | Upotreba kanabinoida u lečenju atoničnih napada kod lenoks-gastoovog sindroma | |
| HK1223615A1 (zh) | 多環氨基甲酰基吡啶酮化合物和其用於治療 感染的用途 | |
| HUE061618T2 (hu) | Vegyület szemrendellenességek kezelésére | |
| EP3620203C0 (en) | VASCULAR TREATMENT DEVICES | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| LT3139903T (lt) | Vandeninis akių tirpalas ir sausų akių sindromo gydymo būdas | |
| IL260684B (en) | Treatment for modulating gut microbiota | |
| HK1219653A1 (zh) | 治療線粒體疾病的方法 | |
| DK3099356T3 (da) | Medikamentadministrationsanordning | |
| HK1215369A1 (zh) | 可植入的管腔裝置 | |
| ZA201902090B (en) | Combination treatments comprising administration of imidazopyrazinones | |
| HUE049413T2 (hu) | Nazális porkészítmény hipoglikémia kezelésére | |
| DK3380146T3 (da) | Medikamentadministrationsanordning | |
| HUE061741T2 (hu) | Maszk szemszárazság kezelésére | |
| LT3229790T (lt) | Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme | |
| DK2976101T3 (da) | Behandlingsfremgangsmåde | |
| DK3519025T3 (da) | Indgivelsesanordning | |
| IL252158B (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| DK3099357T3 (da) | Medikamentadministrationsanordning | |
| DK3472739T3 (da) | Procedurebakkeadministration | |
| DK3041506T3 (da) | Behandlingsfremgangsmåde |